

Lasse Kj r

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/845517/publications.pdf>

Version: 2024-02-01

29
papers

805
citations

516710

16
h-index

501196

28
g-index

29
all docs

29
docs citations

29
times ranked

897
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic profiling of a randomized trial of interferon- β vs hydroxyurea in MPN reveals mutation-specific responses. <i>Blood Advances</i> , 2022, 6, 2107-2119.	5.2	26
2	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	0
3	Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study. <i>British Journal of Haematology</i> , 2021, 193, 83-92.	2.5	6
4	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 637420.	2.8	29
5	Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study. <i>Redox Biology</i> , 2021, 41, 101895.	9.0	8
6	Data-driven analysis of the kinetics of the <i>JAK2V617F</i> allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. <i>European Journal of Haematology</i> , 2021, 107, 624-633.	2.2	6
7	Dose-dependent mathematical modeling of interferon- β treatment for personalized treatment of myeloproliferative neoplasms. <i>Computational and Systems Oncology</i> , 2021, 1, .	1.5	2
8	The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera. <i>European Journal of Haematology</i> , 2020, 104, 46-54.	2.2	5
9	Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2.3 million people. <i>British Journal of Haematology</i> , 2020, 189, 323-334.	2.5	27
10	Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 2100.	3.7	19
11	Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment. <i>Cancers</i> , 2020, 12, 2119.	3.7	7
12	Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer's disease: evidences and perspectives. <i>Journal of Neuroinflammation</i> , 2020, 17, 248.	7.2	8
13	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 315-324.	4.2	12
14	Data-driven analysis of JAK2 V617F kinetics during interferon- α 2 treatment of patients with polycythemia vera and related neoplasms. <i>Cancer Medicine</i> , 2020, 9, 2039-2051.	2.8	21
15	Cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon- β 2, or combination treatment. <i>European Journal of Haematology</i> , 2019, 103, 351-361.	2.2	6
16	Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. <i>Blood</i> , 2019, 134, 469-479.	1.4	139
17	Variant-specific discrepancy when quantitating <i>BCR-ABL1</i> $e13a2$ and $e14a2$ transcripts using the Europe Against Cancer qPCR assay. <i>European Journal of Haematology</i> , 2019, 103, 26-34.	2.2	26
18	JAK2V617F but not CALR mutations confer increased molecular responses to interferon- β via JAK1/STAT1 activation. <i>Leukemia</i> , 2019, 33, 995-1010.	7.2	43

#	ARTICLE	IF	CITATIONS
19	Bridging blood cancers and inflammation: The reduced Cancitis model. <i>Journal of Theoretical Biology</i> , 2019, 465, 90-108.	1.7	11
20	Sorted peripheral blood cells identify <i>CALR</i> mutations in B- and T-lymphocytes. <i>Leukemia and Lymphoma</i> , 2018, 59, 973-977.	1.3	15
21	Safety and efficacy of combination therapy of interferon- α 2 and ruxolitinib in polycythemia vera and myelofibrosis. <i>Cancer Medicine</i> , 2018, 7, 3571-3581.	2.8	38
22	Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. <i>PLoS ONE</i> , 2017, 12, e0183620.	2.5	51
23	Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. <i>PLoS ONE</i> , 2016, 11, e0165336.	2.5	38
24	Interferon- α 2 induces marked alterations in circulating regulatory T cells, <i>NK</i> cell subsets, and dendritic cells in patients with <i>JAK2</i> V617F-positive essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 97, 83-92.	2.2	30
25	Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. <i>Leukemia and Lymphoma</i> , 2016, 57, 348-354.	1.3	40
26	Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression. <i>PLoS ONE</i> , 2014, 9, e112786.	2.5	59
27	Rapid Clearance Of JAK2 V617F Allele Burden In Patient With Advanced Polycythemia Vera (PV) During Combination Therapy With Ruxolitinib and Peg-Interferon Alpha-2a. <i>Blood</i> , 2013, 122, 5241-5241.	1.4	5
28	A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden. <i>PLoS ONE</i> , 2012, 7, e33100.	2.5	18
29	The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. <i>Haematologica</i> , 2011, 96, 450-453.	3.5	110